MY141144A - 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases - Google Patents

1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Info

Publication number
MY141144A
MY141144A MYPI20010900A MYPI20010900A MY141144A MY 141144 A MY141144 A MY 141144A MY PI20010900 A MYPI20010900 A MY PI20010900A MY PI20010900 A MYPI20010900 A MY PI20010900A MY 141144 A MY141144 A MY 141144A
Authority
MY
Malaysia
Prior art keywords
compounds
pyrimido
dipyrimidin
disubstituted
dihydro
Prior art date
Application number
MYPI20010900A
Other languages
English (en)
Inventor
Jerry L Adams
Jeffrey C Boehm
John J Taggart
Ralph F Hall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MY141144A publication Critical patent/MY141144A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
MYPI20010900A 2000-03-02 2001-02-28 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases MY141144A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18641900P 2000-03-02 2000-03-02

Publications (1)

Publication Number Publication Date
MY141144A true MY141144A (en) 2010-03-15

Family

ID=22684876

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20010900A MY141144A (en) 2000-03-02 2001-02-28 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Country Status (25)

Country Link
EP (1) EP1265900B1 (enExample)
JP (1) JP2003525295A (enExample)
KR (1) KR100806978B1 (enExample)
CN (1) CN100482664C (enExample)
AR (2) AR030053A1 (enExample)
AT (1) ATE362473T1 (enExample)
AU (2) AU3999201A (enExample)
BR (1) BR0108715A (enExample)
CA (1) CA2402092C (enExample)
CY (1) CY1106816T1 (enExample)
CZ (1) CZ20022933A3 (enExample)
DE (1) DE60128457T2 (enExample)
DK (1) DK1265900T3 (enExample)
ES (1) ES2287107T3 (enExample)
HU (1) HUP0204431A3 (enExample)
IL (3) IL151426A0 (enExample)
MX (1) MXPA02008588A (enExample)
MY (1) MY141144A (enExample)
NO (1) NO326409B1 (enExample)
NZ (1) NZ520914A (enExample)
PL (1) PL358280A1 (enExample)
PT (1) PT1265900E (enExample)
TW (1) TWI290926B (enExample)
WO (1) WO2001064679A1 (enExample)
ZA (1) ZA200207017B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139599A0 (en) 1998-05-26 2002-02-10 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
NZ524806A (en) * 2000-10-23 2006-03-31 Smithkline Beecham Corp Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
CA2431904A1 (en) 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
SI1474395T1 (sl) 2002-02-12 2008-02-29 Smithkline Beecham Corp Nikotinamidni derivati, uporabni kot inhibitorji p38
RU2293731C2 (ru) 2002-02-13 2007-02-20 Ф.Хоффманн-Ля Рош Аг Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение
EP1499320B1 (en) * 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
GB0218800D0 (en) * 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
AU2003262911A1 (en) 2002-08-29 2004-03-19 Scios Inc. Methods of promoting osteogenesis
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
EP1615928A1 (en) 2003-04-10 2006-01-18 F.Hoffmann-La Roche Ag Pyrimido compounds
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
PL1699800T3 (pl) * 2003-12-23 2010-07-30 Novartis Ag Bicykliczne heterocykliczne inhibitory kinazy p-38
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP5201817B2 (ja) * 2005-10-28 2013-06-05 大塚製薬株式会社 医薬組成物
JP2009542817A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
JP2009542818A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
KR101040394B1 (ko) * 2010-05-18 2011-06-09 (주)이성산업 역화 방지 기능을 갖는 야외용 가스 히터
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CN106831722B (zh) * 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
UY37918A (es) 2017-10-05 2019-04-30 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2022373595A1 (en) 2021-10-20 2024-05-02 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
CA2262692C (en) * 1996-08-06 2002-06-11 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
IL139599A0 (en) * 1998-05-26 2002-02-10 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU4429799A (en) * 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
CA2347474C (en) * 1998-10-23 2008-08-26 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles

Also Published As

Publication number Publication date
NZ520914A (en) 2004-03-26
KR20020082858A (ko) 2002-10-31
IL189865A0 (en) 2008-08-07
BR0108715A (pt) 2004-04-27
NO20024134L (no) 2002-10-24
DK1265900T3 (da) 2007-09-24
KR100806978B1 (ko) 2008-02-25
AR030053A1 (es) 2003-08-13
ES2287107T3 (es) 2007-12-16
CZ20022933A3 (cs) 2003-02-12
CY1106816T1 (el) 2012-01-25
IL151426A (en) 2011-01-31
ATE362473T1 (de) 2007-06-15
EP1265900B1 (en) 2007-05-16
PL358280A1 (en) 2004-08-09
NO20024134D0 (no) 2002-08-30
DE60128457D1 (de) 2007-06-28
CA2402092A1 (en) 2001-09-07
IL151426A0 (en) 2003-04-10
EP1265900A4 (en) 2004-11-10
PT1265900E (enExample) 2007-08-22
AU2001239992B2 (en) 2005-09-01
CA2402092C (en) 2012-01-24
HUP0204431A1 (hu) 2003-04-28
ZA200207017B (en) 2004-02-26
NO326409B1 (no) 2008-12-01
MXPA02008588A (es) 2003-02-24
WO2001064679A1 (en) 2001-09-07
JP2003525295A (ja) 2003-08-26
DE60128457T2 (de) 2008-01-17
HUP0204431A3 (en) 2006-01-30
AU3999201A (en) 2001-09-12
CN1422273A (zh) 2003-06-04
EP1265900A1 (en) 2002-12-18
HK1052932A1 (en) 2003-10-03
CN100482664C (zh) 2009-04-29
TWI290926B (en) 2007-12-11
AR040075A2 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) Compuestos novedosos.
EP1112070A4 (en) NEW SUBSTITUTED TRIAZOLE COMPOUNDS
EP1233951A4 (en) 3,4-DIHYDRO (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P38 KINASE INHIBITORS
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
WO2004021979A3 (en) PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
MXPA06001134A (es) Inhibidores de la actividad de la proteina cinasa b.
IL164606A0 (en) Novel compounds
WO2004073628A3 (en) Novel compounds
TW200724142A (en) Novel compounds
EP1235814A4 (en) 3,4-DIHYDRO- (1H) QUINAZOLINE-2-ONE COMPOUNDS FOR USE AS CSBP / p38 KINASE INHIBITORS
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.
MY145907A (en) Novel 2,4,8-trisubstitute d-8h-pyrido[2,3-d) pyrimidin-7-one compounds
EP1842851A3 (en) Novel compounds